168 related articles for article (PubMed ID: 16490810)
1. Isoflavones inhibit nicotine C-oxidation catalyzed by human CYP2A6.
Nakajima M; Itoh M; Yamanaka H; Fukami T; Tokudome S; Yamamoto Y; Yamamoto H; Yokoi T
J Clin Pharmacol; 2006 Mar; 46(3):337-44. PubMed ID: 16490810
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effects of neurotransmitters and steroids on human CYP2A6.
Higashi E; Nakajima M; Katoh M; Tokudome S; Yokoi T
Drug Metab Dispos; 2007 Apr; 35(4):508-14. PubMed ID: 17237153
[TBL] [Abstract][Full Text] [Related]
3. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans.
Nakajima M; Kwon JT; Tanaka N; Zenta T; Yamamoto Y; Yamamoto H; Yamazaki H; Yamamoto T; Kuroiwa Y; Yokoi T
Clin Pharmacol Ther; 2001 Jan; 69(1):72-8. PubMed ID: 11180041
[TBL] [Abstract][Full Text] [Related]
4. Role of human cytochrome P4502A6 in C-oxidation of nicotine.
Nakajima M; Yamamoto T; Nunoya K; Yokoi T; Nagashima K; Inoue K; Funae Y; Shimada N; Kamataki T; Kuroiwa Y
Drug Metab Dispos; 1996 Nov; 24(11):1212-7. PubMed ID: 8937855
[TBL] [Abstract][Full Text] [Related]
5. A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo.
Fukami T; Nakajima M; Yoshida R; Tsuchiya Y; Fujiki Y; Katoh M; McLeod HL; Yokoi T
Clin Pharmacol Ther; 2004 Dec; 76(6):519-27. PubMed ID: 15592323
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations.
Nakajima M; Fukami T; Yamanaka H; Higashi E; Sakai H; Yoshida R; Kwon JT; McLeod HL; Yokoi T
Clin Pharmacol Ther; 2006 Sep; 80(3):282-97. PubMed ID: 16952495
[TBL] [Abstract][Full Text] [Related]
7. Porcine CYP2A polymorphisms and activity.
Skaanild MT; Friis C
Basic Clin Pharmacol Toxicol; 2005 Aug; 97(2):115-21. PubMed ID: 15998359
[TBL] [Abstract][Full Text] [Related]
8. Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes.
Yamazaki H; Inoue K; Hashimoto M; Shimada T
Arch Toxicol; 1999 Mar; 73(2):65-70. PubMed ID: 10350185
[TBL] [Abstract][Full Text] [Related]
9. Nicotine metabolism and CYP2A6 allele frequencies in Koreans.
Kwon JT; Nakajima M; Chai S; Yom YK; Kim HK; Yamazaki H; Sohn DR; Yamamoto T; Kuroiwa Y; Yokoi T
Pharmacogenetics; 2001 Jun; 11(4):317-23. PubMed ID: 11434509
[TBL] [Abstract][Full Text] [Related]
10. Modified nicotine metabolism in transgenic tobacco plants expressing the human cytochrome P450 2A6 cDNA.
Dueckershoff K; Unger M; Frank A; Gillam EM; Guengerich FP; Warzecha H
FEBS Lett; 2005 Apr; 579(11):2480-4. PubMed ID: 15848192
[TBL] [Abstract][Full Text] [Related]
11. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity.
Dempsey D; Tutka P; Jacob P; Allen F; Schoedel K; Tyndale RF; Benowitz NL
Clin Pharmacol Ther; 2004 Jul; 76(1):64-72. PubMed ID: 15229465
[TBL] [Abstract][Full Text] [Related]
12. CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking.
Malaiyandi V; Goodz SD; Sellers EM; Tyndale RF
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1812-9. PubMed ID: 17035386
[TBL] [Abstract][Full Text] [Related]
13. Gene-gene interactions between CYP2B6 and CYP2A6 in nicotine metabolism.
Ring HZ; Valdes AM; Nishita DM; Prasad S; Jacob P; Tyndale RF; Swan GE; Benowitz NL
Pharmacogenet Genomics; 2007 Dec; 17(12):1007-15. PubMed ID: 18004205
[TBL] [Abstract][Full Text] [Related]
14. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine.
Benowitz NL; Swan GE; Jacob P; Lessov-Schlaggar CN; Tyndale RF
Clin Pharmacol Ther; 2006 Nov; 80(5):457-67. PubMed ID: 17112802
[TBL] [Abstract][Full Text] [Related]
15. In vivo evaluation of coumarin and nicotine as probe drugs to predict the metabolic capacity of CYP2A6 due to genetic polymorphism in Thais.
Peamkrasatam S; Sriwatanakul K; Kiyotani K; Fujieda M; Yamazaki H; Kamataki T; Yoovathaworn K
Drug Metab Pharmacokinet; 2006 Dec; 21(6):475-84. PubMed ID: 17220563
[TBL] [Abstract][Full Text] [Related]
16. A novel CYP2A6*20 allele found in African-American population produces a truncated protein lacking enzymatic activity.
Fukami T; Nakajima M; Higashi E; Yamanaka H; McLeod HL; Yokoi T
Biochem Pharmacol; 2005 Sep; 70(5):801-8. PubMed ID: 15993850
[TBL] [Abstract][Full Text] [Related]
17. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes.
Messina ES; Tyndale RF; Sellers EM
J Pharmacol Exp Ther; 1997 Sep; 282(3):1608-14. PubMed ID: 9316878
[TBL] [Abstract][Full Text] [Related]
18. Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes.
Nakajima M; Yamamoto T; Nunoya K; Yokoi T; Nagashima K; Inoue K; Funae Y; Shimada N; Kamataki T; Kuroiwa Y
J Pharmacol Exp Ther; 1996 May; 277(2):1010-5. PubMed ID: 8627511
[TBL] [Abstract][Full Text] [Related]
19. Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans.
Nakajima M; Yamagishi S; Yamamoto H; Yamamoto T; Kuroiwa Y; Yokoi T
Clin Pharmacol Ther; 2000 Jan; 67(1):57-69. PubMed ID: 10668854
[TBL] [Abstract][Full Text] [Related]
20. Nicotine 5'-oxidation and methyl oxidation by P450 2A enzymes.
Murphy SE; Raulinaitis V; Brown KM
Drug Metab Dispos; 2005 Aug; 33(8):1166-73. PubMed ID: 15860657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
